⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Global Medical Radiation Detection Devices Market to Increase at a Steady Growth Rate of ~7% by 2032 | DelveInsight
globenewswire.com
VMI
SENS
HOG
GEHC
PHG
GM
TMO
PERI
MED
BIIB
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus
prnewswire.com
BIIB
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
globenewswire.com
BIIB
Boehringer Ingelheim und Simcere gehen Partnerschaft ein, um eine dual-zielgerichtete Antikörperbehandlung zur Behandlung von entzündlichen Darmerkrankungen voranzutreiben USA - Deutsch USA - English USA - English USA - Nederlands USA - Français
prnewswire.com
BIIB
App Test Automation Industry Research 2026 - Global Market Size, Share, Trends, Opportunities, and Forecasts, 2021-2025 & 2026-2031
globenewswire.com
LOGI
MSFT
GOOG
AMZN
IBM
ORCL
INTC
NVDA
CRM
ADBE
SAP
EA
TTWO
ROKU
NFLX
DIS
CMCSA
TCOM
MELI
SHOP
PYPL
UBER
LYFT
DDOG
PANW
CRWD
ZS
NOW
TWLO
SNOW
PLTR
AI
STX
WDC
HPQ
DELL
HPE
QCOM
MRVL
AMD
MU
AMAT
LRCX
KLAC
ASML
GLW
AVGO
NXPI
TER
KEYS
NI
CHKP
FTNT
PPC
LULU
SIRI
BBY
TJX
LOW
HD
CAT
BA
GD
LMT
RTX
HON
GE
MMM
AXP
JPM
BAC
WFC
C
GS
MS
V
MA
PG
KO
PEP
MCD
SBUX
VZ
T
CHTR
TMUS
AMGN
BMY
PFE
JNJ
MRK
ABBV
LLY
GILD
BIIB
REGN
VRTX
AZN
SNY
NVS
XOM
CVX
SHEL
BABA
JD
NTES
PDD
EDU
TAL
BIDU
VIPS
CPRT
Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten USA - Nederlands USA - English USA - English USA - Français
prnewswire.com
BIIB
Boehringer Ingelheim et Simcere s'associent pour développer un traitement par anticorps à double cible afin de répondre aux besoins non satisfaits dans le domaine des maladies inflammatoires chroniques de l'intestin USA - Français USA - English USA -
prnewswire.com
BIIB
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease USA - English USA - English
prnewswire.com
BIIB
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
globenewswire.com
BIIB
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB